Compare Stocks → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSE:GBSNASDAQ:INBSNASDAQ:MOTSNASDAQ:NVIV Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGBSGBS$2.47-3.9%$4.05$0.36▼$2.89$36.78M1.32955,325 shs50,467 shsINBSIntelligent Bio Solutions$2.47-3.9%$4.07$2.28▼$49.20$7.02M4.822.57 million shs50,467 shsMOTSMotus GI$0.08$0.50$0.05▼$23.40$402K1.31.37 million shs79,947 shsNVIVInVivo Therapeutics$0.58$0.22▼$2.40$997K0.658.25 million shs1.89 million shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGBSGBS-11.15%-11.79%-42.15%+997.29%-5.00%INBSIntelligent Bio Solutions-3.89%-11.79%-42.15%-6.01%-91.90%MOTSMotus GI+3.90%+14.29%-81.47%-91.95%-99.34%NVIVInVivo Therapeutics0.00%0.00%0.00%-53.25%-76.24%These AI trades triggered this morning (545% return) (Ad)If you think a market crash is possible in 2024, I don't know why you're not using this yet. Click Here To Get Your Free CopyMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGBSGBSN/AN/AN/AN/AN/AN/AN/AN/AINBSIntelligent Bio SolutionsN/AN/AN/AN/AN/AN/AN/AN/AMOTSMotus GI1.2042 of 5 stars3.53.00.00.00.60.00.6NVIVInVivo TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGBSGBSN/AN/AN/AN/AINBSIntelligent Bio SolutionsN/AN/AN/AN/AMOTSMotus GI3.00Buy$28.8835,993.75% UpsideNVIVInVivo TherapeuticsN/AN/AN/AN/ACurrent Analyst RatingsSales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGBSGBS$440K83.59N/AN/A$0.44 per share5.61INBSIntelligent Bio Solutions$1.26M5.57N/AN/A$18.99 per share0.13MOTSMotus GI$319K1.26N/AN/A$1.74 per share0.05NVIVInVivo TherapeuticsN/AN/AN/AN/A$6.48 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGBSGBS-$8.31M-$0.56N/AN/AN/AN/A-85.64%-54.42%N/AINBSIntelligent Bio Solutions-$10.63M-$106.15N/AN/AN/A-544.63%-266.16%-96.52%5/9/2024 (Estimated)MOTSMotus GI-$12.87M-$28.55N/A∞N/A-4,033.54%N/A-110.70%5/8/2024 (Estimated)NVIVInVivo Therapeutics-$10.49MN/A0.00N/AN/AN/A-75.04%-65.01%N/ALatest NVIV, MOTS, INBS, and GBS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/18/2024Q4 2023MOTSMotus GIN/A-$4.13-$4.13-$3.78N/A$0.06 million2/9/2024Q2 2024INBSIntelligent Bio Solutions-$3.24-$2.07+$1.17-$2.07N/A$0.76 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGBSGBSN/AN/AN/AN/AN/AINBSIntelligent Bio SolutionsN/AN/AN/AN/AN/AMOTSMotus GIN/AN/AN/AN/AN/ANVIVInVivo TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGBSGBSN/A2.332.33INBSIntelligent Bio Solutions0.070.570.39MOTSMotus GI0.461.761.69NVIVInVivo TherapeuticsN/A14.3014.30OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGBSGBS2.79%INBSIntelligent Bio Solutions32.97%MOTSMotus GI20.06%NVIVInVivo Therapeutics13.78%Insider OwnershipCompanyInsider OwnershipGBSGBS0.27%INBSIntelligent Bio Solutions0.28%MOTSMotus GI1.57%NVIVInVivo Therapeutics2.45%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableGBSGBS714.89 million14.85 millionNot OptionableINBSIntelligent Bio Solutions512.84 million2.84 millionNot OptionableMOTSMotus GI155.03 million4.95 millionNot OptionableNVIVInVivo Therapeutics63.11 million3.03 millionNot OptionableNVIV, MOTS, INBS, and GBS HeadlinesSourceHeadlineInterview: Emmes Mindy Leffler - are video based assessments the way forward to evaluate patients at home?outsourcing-pharma.com - April 8 at 7:38 PMGut health supplements are everywhere – but which are the best ones for *you*?msn.com - March 28 at 4:18 PMDrug discovery and global player, Cresset, moves team into Boston marking major turning pointoutsourcing-pharma.com - March 12 at 7:43 PMInVivo Therapeutics Holdings Corporationcnn.com - February 15 at 12:40 AMInVivo Therapeutics Holdings Corp.wsj.com - February 14 at 2:40 PMFirm Retention Summary: InVivo Therapeutics Holdingswsj.com - February 13 at 6:29 PMInVivo Therapeutics Holdings Corp (NVIV)investing.com - February 7 at 11:49 PMBob Langer-founded device-maker declares bankruptcybizjournals.com - February 6 at 4:38 PMWhy Is InVivo Therapeutics (NVIV) Stock Up 61% Today?investorplace.com - February 6 at 9:12 AMInVivo Therapeutics Shares Plumb New Depths After Bankruptcy Filingmarketwatch.com - February 1 at 2:09 PMSpinal Cord Injury Therapeutics Market surpass $10.7 billion by 2031 - Exclusive Report by Coherent Market Insightsprnewswire.co.uk - January 31 at 12:06 PMInVivo Therapeutics Holdings: Submission Of Matters To A Vote Of Security Holderscbonds.com - January 5 at 10:04 AMInVivo Biosystems Secures New Investment to Accelerate CRISPR Innovationpharmiweb.com - January 4 at 1:33 PMInVivo Therapeutics Holdings Corp NVIVmorningstar.com - November 10 at 7:26 AMApollo, Nimbus lead bumper week for biotech financingspharmaphorum.com - September 8 at 9:41 AMAustralia’s United Malt OKs $1-B takeover offer from France’s InVivobusiness.inquirer.net - July 2 at 10:09 PMSpinal Cord Trauma Treatment Market Analysis: Examining Trends and Forecasting Revenue Growth with an estimated CAGR 6.2% from 2023-2030marketwatch.com - June 22 at 5:14 PMRing Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate Strategybenzinga.com - May 1 at 12:30 PMWhy InVivo Therapeutics Shares Are Plunging Todayfinance.yahoo.com - March 17 at 1:53 AMInVivo seeks longer-term control in Casino-Teract retail tie-upmsn.com - March 10 at 6:45 PMWhy Barnes & Noble Education Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarketmsn.com - March 10 at 6:45 PMU.S. stocks lower at close of trade; Dow Jones Industrial Average down 1.66%msn.com - March 10 at 3:10 AMWhy JD.com Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Thursday's Mid-Day Sessionmsn.com - March 9 at 5:08 PMInVivo : INSPIRE 2.0 Study In Acute Spinal Cord Injury Fails To Meet Primary Endpointmarkets.businessinsider.com - March 9 at 5:08 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsGBSNYSE:GBSGBS Inc. operates as a biosensor diagnostic technology company in the Asia-Pacific and North America. It offers Saliva Glucose Biosensor, an organic thin-film transistor for diabetes management that measures glucose in saliva. The company also focuses on developing SARS-CoV-2 Biosensor, a biosensor test can be used as a complement to the (RNA) virus detection test; and a biosensor platform comprising of biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. GBS Inc. has a research agreement with Johns Hopkins Bloomberg School of Public Health for the development of saliva-based diagnostic tests. The company was formerly known as Glucose Biosensor Systems (Greater China) Holdings, Inc. and changed its name to GBS Inc. in September 2019. The company was incorporated in 2016 and is headquartered in New York, New York. GBS Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.Intelligent Bio SolutionsNASDAQ:INBSIntelligent Bio Solutions Inc., a medical technology company, developing non-invasive, real-time monitoring, and diagnostic tests for patients and their primary health practitioners. It offers saliva glucose biosensor for diabetes management that measures glucose in saliva. The company also provides intelligent fingerprinting drug screening system, a revolutionizing portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields; and biosensor platform for biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was formerly known as GBS Inc. and changed its name to Intelligent Bio Solutions Inc. in October 2022. The company was incorporated in 2016 and is headquartered in New York, New York. Intelligent Bio Solutions Inc. is a subsidiary of Life Science Biosensor Diagnostics Pty Ltd.Motus GINASDAQ:MOTSMotus GI Holdings, Inc. operates as a medical technology company in the United States. It develops Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during the colonoscopy and facilitates upper gastrointestinal endoscopy procedures. The company was formerly known as Eight-Ten Merger Corp. and changed its name to Motus GI Holdings, Inc. in November 2016. The company was founded in 2008 and is based in Fort Lauderdale, Florida.InVivo TherapeuticsNASDAQ:NVIVInVivo Therapeutics Holdings Corp. operates as a research and clinical-stage biomaterials and biotechnology company in the United States. The company engages in developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries (SCI). It is developing a Neuro-Spinal Scaffold implant comprise of biocompatible and bioresorbable polymers, which includes Poly lactic-co-glycolic acid, a polymer which is widely used in resorbable sutures and provides the biocompatible support for Neuro-Spinal Scaffold implant; and Poly-L-Lysine, a positively charged polymer used to coat surfaces to promote cellular attachment. The company was incorporated in 2003 and is headquartered in Cambridge, Massachusetts. On February 1, 2024, InVivo Therapeutics Holdings Corp. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. It is in joint administration with InVivo Therapeutics Corporation. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.